Triple

T20301446
Position Surface form Disambiguated ID Type / Status
Subject Alexion Pharmaceuticals E505487 entity
Predicate notableProduct P1448 FINISHED
Object Strensiq NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Strensiq | Statement: [Alexion Pharmaceuticals, notableProduct, Strensiq]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Strensiq
Context triple: [Alexion Pharmaceuticals, notableProduct, Strensiq]
  • A. Evrysdi
    Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
  • B. Rinvoq
    Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
  • C. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • D. Emgality
    Emgality is a prescription monoclonal antibody medication used for the prevention and treatment of migraine and cluster headaches.
  • E. Taltz
    Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Strensiq
Target entity description: Strensiq is a prescription enzyme replacement therapy used to treat patients with perinatal-, infantile- and juvenile-onset hypophosphatasia, a rare genetic bone disorder.
  • A. Evrysdi
    Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
  • B. Rinvoq
    Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
  • C. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • D. Emgality
    Emgality is a prescription monoclonal antibody medication used for the prevention and treatment of migraine and cluster headaches.
  • E. Taltz
    Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e0b4b8ab648190906e18538c250148 completed April 16, 2026, 10:06 a.m.
NER Named-entity recognition batch_69e6770c700c81909da247cef0d0f1eb completed April 20, 2026, 6:57 p.m.
Created at: April 16, 2026, 11:17 a.m.